- Home
- AAL vs MDGL Comparison
AAL vs MDGL Comparison
Compare AAL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAL | MDGL |
|---|---|---|
| Founded | 1930 | 2011 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.8B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AAL | MDGL |
|---|---|---|
| Price | $15.28 | $546.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | $15.59 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 145.7M | 307.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,633,000,000.00 | $180,133,000.00 |
| Revenue This Year | $12.17 | $58.39 |
| Revenue Next Year | $4.62 | $48.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $10.09 | $286.75 |
| 52 Week High | $18.79 | $615.00 |
Technical Indicators
Market Signals| Indicator | AAL | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 55.16 |
| Support Level | $15.02 | $529.02 |
| Resistance Level | $15.39 | $545.29 |
| Average True Range (ATR) | 0.64 | 22.21 |
| MACD | -0.37 | -0.37 |
| Stochastic Oscillator | 7.92 | 56.99 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.